The Technical Analyst
Bicycle Therapeutics PLC [BCYC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Bicycle Therapeutics PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.49% $22.68
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 962.35 mill |
| EPS: | -5.08 |
| P/E: | -4.46 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 42.43 mill |
| Avg Daily Volume: | 0.401 mill |
| RATING 2024-04-23 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.46 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.76x |
| Company: PE -4.46 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 21.36 - 24.00 ( +/- 5.80%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-18 | Baker Bros. Advisors Lp | Buy | 12 000 | American Depositary Shares |
| 2024-04-18 | Baker Bros. Advisors Lp | Buy | 12 000 | American Depositary Shares |
| 2024-04-18 | Baker Bros. Advisors Lp | Buy | 24 000 | Share Option (Right to Buy) |
| 2024-04-18 | Baker Bros. Advisors Lp | Buy | 0 | American Depositary Shares |
| 2024-04-18 | Baker Bros. Advisors Lp | Buy | 0 | American Depositary Shares |
| INSIDER POWER |
|---|
| 72.49 |
| Last 94 transactions |
| Buy: 1 498 500 | Sell: 230 741 |
Forecast:
16:00 - $22.68
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $22.68
Forecast 2: 16:00 - $22.68
Forecast 3: 16:00 - $22.68
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $22.68 (0.49% ) |
| Volume | 0.163 mill |
| Avg. Vol. | 0.401 mill |
| % of Avg. Vol | 40.72 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BCYC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:33 | sell | $16.78 | N/A | Active |
|---|
BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Latest Press Releases
2024-04-02 07:00:00 - Press Release
Bicycle Therapeutics To Participate In The 23rd Annual Needham Virtual Healthcare Conference
Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that management will participate in a fireside chat at the 23rd annual needham virtual healthcare conference on april 9, 2024, at 11 a.m. et. a live webcast of the fireside chat will be accessible from the investor section of the company's websi.
2024-03-05 16:35:00 - Press Release
Bicycle Therapeutics To Present At The Aacr Annual Meeting 2024
Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced the acceptance of three abstracts for poster presentation at the american association for cancer research (aacr) annual meeting 2024, taking place in san diego on april 5-10. poster presentation details: title: bicycle toxin conjugates® for the.
2024-02-28 07:00:00 - Press Release
Bicycle Therapeutics To Participate In Upcoming Investor Conferences
Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that management will participate in the following investor conferences in march: td cowen 44th annual health care conference on wednesday, march 6, 2024; fireside chat at 11:10 a.m. et leerink partners global biopharma conference on monday, marc.
2024-02-20 07:05:00 - Press Release
Bicycle Therapeutics Reports Recent Business Progress And Fourth Quarter And Full Year 2023 Financial Results
Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today reported financial results for the fourth quarter and full year ended december 31, 2023, and provided recent corporate updates. “2023 was a pivotal year for our company, during which we achieved significant progress across our nectin-4 and epha2 clinical.
2024-02-07 07:00:00 - Press Release
Bicycle Therapeutics To Participate In The Oppenheimer 34th Annual Healthcare Life Sciences Conference
Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq:bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that management will participate in a fireside chat at the oppenheimer 34th annual healthcare life sciences conference on february 14, 2024, at 10 a.m. et. a live webcast of the fireside chat will be accessible from the investor section of the compan.
Latest News
2024-03-25 13:07:32 - Seeking Alpha
2 More Potential Biotech Buyout Targets
M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.
2024-03-05 16:35:00 - Business Wire
Bicycle Therapeutics to Present at the AACR Annual Meeting 2024
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of three abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego on April 5-10. Poster Presentation Details: Title: Bicycle Toxin Conjugates® for the.
2023-09-12 09:05:13 - Zacks Investment Research
Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up
Bicycle (BCYC) aligns with the FDA on the design of a mid-late-stage registrational study for its bladder cancer drug, BT8009, with the potential to support its accelerated approval. The stock rises 9%.
2023-09-12 08:20:15 - Zacks Investment Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains?
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2023-09-11 14:19:40 - The Motley Fool
Why Shares of Bicycle Therapeutics Were Rising on Monday
Bicycle Therapeutics has 14 programs in its pipeline. The company is a clinical-stage biotech.
2023-09-05 07:00:00 - Business Wire
Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023, at 10:10 a.m. ET. A live webcast of the fireside chat will be accessible in the Investors & Media s.
2023-07-31 19:07:20 - Seeking Alpha
Bicycle Therapeutics: Decent Upside Opportunity, Mid-Stage Data Readouts Due
Bicycle Therapeutics is an intriguing play in the drug development space. Using its fully synthetic short peptides, the company has developed two mid-stage oncology assets that have achieved some results of interest in urothelial / ovarian cancers. The company also has numerous potentially lucrative co-development opportunities with the likes of Roche, Novartis, Ionis Pharmaceuticals.
2023-07-14 08:08:14 - Zacks Investment Research
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Soars 19.3%: Is Further Upside Left in the Stock?
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2023-07-13 18:40:28 - The Motley Fool
Why Bicycle Therapeutics Stock Raced Ahead Today
The U.K.-based biotech announced a fresh offering of its ADSes. It's seeking to net around $187 million in proceeds with the issue.
2023-05-14 07:16:59 - Seeking Alpha
Bicycle Therapeutics: Not Much Differentiation Between Bicycles And mAbs Yet
BCYC's distinction is that it is founded by a Nobel laureate. However, unless it can differentiate its product's efficacy from that of mAbs, that may be its only distinction.